Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Clearmind Medicine Inc. (CMND)

NCM · Biotechnology

$1.46-0.14 (-8.92%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$2.2M
P/E (TTM)
EPS
$-159.68
Div Yield
52W Range
$1.43–$524.00
Beta
-1.19

Company overview

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Peers in Biotechnology

All in industry →

Recent press releases

April 2026

3 months ago6-KHealthcare

Executive order and bill boost Clearmind's psychedelic drug development

CMNDClearmind Medicine Inc.

# 📰 What This Document Is This filing is an SEC Form 6-K, which is a type of filing used by foreign private issuers (like Clearmind Medicine) to announce material information to U.S. investors. Essentially, this document is a press release designed to inform the public and potential investors about

Read summaryView on SEC EDGAR

March 2026

4 months ago6-KHealthcare

Clearmind Medicine Inc. — 6-K Filing

CMNDClearmind Medicine Inc.

# 🧾 What This Document Is This is a **6-K filing**, which is a report public foreign companies (like this Canadian one) file with the SEC to share important news. Think of it as a formal press release channel. This specific one announces a positive update from their ongoing clinical trial. 👉 **Th

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Clearmind Medicine Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-09-30 · prior 2025-06-30
224,378 sh+8.9%
1,138 sh+100.0%
2,564 sh0.0%
28,554 sh● NEW

People at Clearmind Medicine Inc.

All people →

No officers or directors have been indexed for Clearmind Medicine Inc..

Quarterly financials

Full financials →
Revenue trend
10/24
NI
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.
CMND (NCM) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal